Vaxxinity, Inc.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Vaxxinity, Inc. is a biotechnology company that develops rationally designed prophylactic and therapeutic vaccines targeting common chronic disorders and infectious diseases with large patient populations and unmet medical needs. The company’s core product portfolio includes synthetic peptide-based Active Immunotherapy Medicines (AIM) platform candidates focused on neurological diseases such as Alzheimer's disease (UB-311), Parkinson’s disease and other synucleinopathies (UB-312), as well as cardiovascular indications including hypercholesterolemia (VXX-401), migraine (UB-313), and an anti-tau candidate for neurodegenerative conditions (VXX-301). Vaxxinity also has an infectious disease vaccine candidate, UB-612, which is in advanced clinical development as a heterologous booster for COVID-19. Operating primarily in the United States, Vaxxinity integrates synthetic peptide technology to stimulate targeted immune responses, aiming to democratize health by offering safer, more convenient, and cost-effective chronic disease medicines. Founded in 2018 and headquartered in Merritt Island, Florida, the company has recently announced a strategic collaboration with the University of Florida for active immunotherapy research in neurodegenerative diseases and with the University of Central Florida on space medicine research. Additionally, Vaxxinity has provided new clinical data presentations and is advancing its pipeline through ongoing trials, reflecting a strategic expansion in both its therapeutic focus and scientific partnerships while voluntarily delisting its Class A common stock to reorganize its operations and capital structure. These developments position Vaxxinity as an innovative player in biotechnology focused on vaccine-based therapies for chronic conditions and infectious diseases.
Vaxxinity (NASDAQ:VAXX) and Evotec (OTCMKTS:EVTCY) Head to Head Comparison
Critical Review: iBio (NYSE:IBIO) versus Vaxxinity (NASDAQ:VAXX)
Congress makes $4.5 trading stocks in a day; Here's the biggest winners
Vaxxinity UB-312 Parkinson's Trial Results Published in Nature Medicine
Why Is Vaxxinity (VAXX) Stock Up 39% Today?
Why Is Vaxxinity (VAXX) Stock Down 58% Today?
Vaxxinity Issues Shareholder Letter
Vaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common Stock
Vaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual Meeting
Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updates
Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson's Disease at AD/PD™ 2024
Vaxxinity's Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data Published
Vaxxinity to Present Clinical and Preclinical Pipeline Data at AD/PD 2024
Vaxxinity Announces Research Collaboration on Active Immunotherapies for Neurodegenerative Diseases with University of Florida
Vaxxinity Announces Collaboration on Space Medicine Research with University of Central Florida
Vaxxinity to Present at the 2024 J.P. Morgan Healthcare Conference
Alzheimer's Disease Space Evolves in 2023: Stocks in Focus
Vaxxinity to Present at Upcoming November Medical and Investor Conferences
Vaxxinity Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Down -22.18% in 4 Weeks, Here's Why You Should You Buy the Dip in Vaxxinity, Inc. (VAXX)